ArticleOncoimmunology2013
The adenosinergic system in cancer: Key therapeutic target.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- CD39American journal of cancer research · 2024Article
- A2A Receptor Contributes to Tumor Progression in P2X7 Null Mice.Frontiers in cell and developmental biology · 2022Article
- AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer.Frontiers in oncology · 2021Article
- Machine and deep learning approaches for cancer drug repurposing.Seminars in cancer biology · 2021Review
- CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.BMC cancer · 2020Article
- CD73: A Promising Biomarker in Cancer Patients.Frontiers in pharmacology · 2020Article
- The yin and yang functions of extracellular ATP and adenosine in tumor immunity.Cancer cell international · 2020Review
- Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes.PloS one · 2020Article
- Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.Frontiers in immunology · 2019Review
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.Journal of translational medicine · 2017Article
- Blockade of adenosine A2A receptor enhances CD8Molecular cancer · 2017Article
- CD73 is associated with poor prognosis in HNSCC.Oncotarget · 2016Article
- A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.Current opinion in pharmacology · 2016Review
- Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.American journal of cancer research · 2014Article
- The roles of CD73 in cancer.BioMed research international · 2014Review
- Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.Neoplasia (New York, N.Y.) · 2013Article
- A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes.Oncoimmunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High amounts of adenosine are released in the tumor mass. Depending on the levels of adenosine, as well as on the receptor subtypes that are expressed by immune cells, adenosine can affect tumor growth in different fashions. Specifically targeting CD73, the rate-limiting enzyme for the extracellular generation of adenosine, or the A3 receptor offers new therapeutic strategies to limit tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.